Allow Deny

This site uses cookies for retargeting.


Mudgil P., M.K.Y. Mustafa N., Al Kaabi M., Al Ketbi M., Abubaid A.
United Arab Emirates University, UAE

Obesity, as an ever-growing epidemic, remains the top contributor to global burden of disease. It not only strains the healthcare systems but also has profound effects on economy and psychology of people suffering. Pancreatic lipase is the primary lipase that hydrolyzes dietary fat molecules in the human digestive tract, converting triacylglycerol substrates to monoacylglycerols and free fatty acids. As obesity is primarily a disorder of lipid metabolism, hence, selective inhibition pancreatic lipase could be targeted for its management. Lipstatin (Orlistat), a FDA approved pancreatic lipase inhibitor obtained from fermentation broth of Actinomycetes remains the most celebrated and successful anti-obesity drug till now. However, excessive inhibition of pancreatic lipase leads to certain discomforts like steatorrhea and isolated cases of organ toxicity. Therefore, in quest of natural and safe inhibitors researchers are screening a lot nutritional products that could potentially possess lipase inhibitory abilities. Till today, the ability of lactic acid bacteria (LAB) towards inhibition of pancreatic lipase remains to be unexplored. Hence, the present study was undertaken to explore the pancreatic lipase inhibitory potential of lactic acid bacteria isolated from camel milk.

Streptococcus and Lactobacillus isolates were isolated from raw milk samples collected from local camel farms of Al Ain, Abu Dhabi, UAE. For screening of lipase inhibitory activity, cell free extracts (CFE) were prepared by incubating washed bacterial cell pellets (250 mg/mL; ww/v) in phosphate buffer saline (PBS) for 12 hours. Inhibitory activities were determined by comparing the release of p-Nitrophenol from P-Nitrophenyl palmitate through porcine pancreatic lipase type VI, in presence and absence of CFE using Orlistat as positive control while PBS, as negative control.

Overall, Lipase inhibitory profile of 97 LAB isolates and 11 reference strains was achieved. A wide variation in inhibitory activities were observed among isolates and reference cultures. Among Streptococcus isolates (52) inhibition ranged from 3.0-99%. 11 isolates possessed potent inhibitory activities comparable or higher than Orlistat (≥ 83%; 2 mg/ mL). Among 45 isolates of Lactobacilli negative inhibition was observed among 13 isolates, while for rest 32 isolates it ranged from 4.0-81%. Inhibition percentage among reference cultures ranged from 3.0-37%. L. acidophilus DSMZ 9126 showed strongest inhibition while L. gasseri 20243 showed lowest inhibition.

These preliminary results definitively demonstrate that LAB isolated from raw camel milk have pancreatic lipase inhibitory activities and can reduce the hydrolysis of dietary fats in vivo. Results obtained also presents the opportunities in the future to use probiotic bacteria in the management of obesity and hyper-lipidaemia. However, as the nature of bacterial metabolites responsible and their fate in gastrointestinal tract is still unclear, hence, further work towards identification of responsible molecules and to better understand its fate under in vivo condition is needed.

Keywords: Pancreatic Lipase Inhibition, Camel milk, Lactic acid Bacteria, Probiotics, Obesity

Mudgil P., et al. (2016). Pancreatic lipase inhibitory activities of lactic acid bacteria isolated from raw camel milk. Conference Proceedings of IPC2016. Paper presented at the International Scientific Conference on Probiotics and Prebiotics, Budapest (p. 49.). IPC2016

To download abstract click here